Current Report Filing (8-k)
July 13 2020 - 6:05AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (date of earliest event reported): July 13, 2020
EQUILLIUM, INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-38692
|
|
82-1554746
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
2223 Avenida de la Playa, Suite 105, La Jolla, CA
|
|
92037
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (858)
412-5302
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, par value $0.0001 per share
|
|
EQ
|
|
The Nasdaq Global Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 8.01 Other Events.
On July 13, 2020, Equillium, Inc. (the Company) announced that a clinical trial conducted by its partner, Biocon
Limited, demonstrated that itolizumab significantly reduced mortality in patients hospitalized with COVID-19 in India and that the Drugs Controller General of India, the regulatory agency that oversees drug
approvals in India, has granted restricted emergency use of itolizumab for the treatment of cytokine release syndrome in COVID-19 patients with moderate to severe acute respiratory distress syndrome in India.
The Company, which has the right to develop and commercialize itolizumab in the U.S., Canada, Australia and New Zealand, is planning to conduct a global randomized, controlled clinical trial of itolizumab in
COVID-19 patients for which it will file a U.S. investigational new drug application. A copy of the press release discussing these matters is filed as Exhibit 99.01, and incorporated by reference in, this
report.
Item 9.01 Financial Statements and Exhibits.
2
SIGNATURE
Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
|
|
|
|
|
|
EQUILLIUM, INC.
|
|
|
|
Date: July 13, 2020
|
|
By:
|
|
/s/ Bruce D. Steel
|
|
|
Bruce D. Steel
|
|
|
President and Chief Executive Officer
|
3
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Jul 2023 to Jul 2024